- Report
- February 2024
- 90 Pages
Asia Pacific
From €4366EUR$4,750USD£3,721GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4366EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4366EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
India
From €4366EUR$4,750USD£3,721GBP
- Report
- August 2023
- 90 Pages
Global
From €4366EUR$4,750USD£3,721GBP
- Report
- October 2022
- 70 Pages
Africa
From €4366EUR$4,750USD£3,721GBP
- Report
- September 2025
- 142 Pages
Global
From €3500EUR$4,079USD£3,087GBP
- Report
- August 2025
- 98 Pages
Global
From €3500EUR$4,079USD£3,087GBP
- Report
- June 2025
- 100 Pages
Europe
From €3631EUR$3,950USD£3,095GBP
- Report
- June 2025
- 81 Pages
Africa, Middle East
From €3171EUR$3,450USD£2,703GBP
- Report
- March 2025
- 145 Pages
Global
From €4458EUR$4,850USD£3,800GBP
- Report
- January 2024
- 120 Pages
United States
€3217EUR$3,500USD£2,742GBP
- Report
- June 2021
- 50 Pages
China
From €2390EUR$2,600USD£2,037GBP
- Report
- February 2024
- 104 Pages
Global
From €3500EUR$4,079USD£3,087GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,079USD£3,087GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,079USD£3,087GBP
- Report
- October 2026
- 50 Pages
Global
From €2436EUR$2,650USD£2,076GBP
- Report
- October 2026
- 50 Pages
Global
From €2436EUR$2,650USD£2,076GBP

Sitagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones in the body. These hormones help to regulate glucose levels in the blood, and can help to reduce the risk of developing type 2 diabetes. Sitagliptin is usually prescribed in combination with other drugs, such as metformin, to help control blood sugar levels. It is also used to treat other conditions, such as polycystic ovary syndrome and non-alcoholic fatty liver disease.
Sitagliptin is available in both oral and injectable forms, and is generally well tolerated with few side effects. It is a relatively new drug, and is becoming increasingly popular as a treatment for endocrine and metabolic disorders.
Some companies in the Sitagliptin market include Merck & Co., Inc., Novartis AG, and Takeda Pharmaceutical Company Limited. Show Less Read more